H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.

Back

ESC Professional Premium Access

H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.

Session: Rhythm control in atrial fibrillation: prognostic and therapeutic implications

Topic: Rhythm Control, Antiarrhythmic Drugs

Speaker: Mr M. Trincado Ave (Santiago de Compostela, ES)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Mauro Trincado Ave

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

0 follower

8 more presentations in this session

Cluster-specific predictors of early rhythm control in contemporary European cohort of patients with atrial fibrillation: The EHRA-PATHS Project

Speaker: Doctor M. Mihajlovic (Belgrade, RS)

Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry

Speaker: Doctor C. Salbach (Heidelberg, DE)

Atrial function after cardioversion in patients with persistent atrial fibrillation

Speaker: Doctor K. Noda (Sendai, JP)

Sinus rhythm maintenance and the changes of echocardiographic parameters in patients with late persistent atrial fibrillation at 6 months after direct current cardioversion

Speaker: Doctor Y. Skybchyk (Kiev, UA)

Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

Speaker: Doctor J. Mason (Salt Lake City, US)

Access the full session

Rhythm control in atrial fibrillation: prognostic and therapeutic implications

Speakers: Mr M. Trincado Ave, Doctor M. Mihajlovic, Doctor C. Salbach, Doctor K. Noda, Doctor Y. Skybchyk...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources